Literature DB >> 22882200

Equivalent survival following liver transplantation in patients with non-alcoholic steatohepatitis compared with patients with other liver diseases.

Christopher Kennedy1, David Redden, Stephen Gray, Devin Eckhoff, Omar Massoud, Brendan McGuire, Basem Alkurdi, Joseph Bloomer, Derek A DuBay.   

Abstract

BACKGROUND: Orthotopic liver transplantation (LT) in non-alcoholic steatohepatitis (NASH) is increasing in parallel with the obesity epidemic.
METHODS: This study retrospectively reviewed the clinical outcomes of LTs in NASH (n = 129) and non-NASH (n = 775) aetiologies carried out at a single centre between 1999 and 2009.
RESULTS: Rates of 1-, 3- and 5-year overall survival in NASH (90%, 88% and 85%, respectively) were comparable with those in non-NASH (92%, 86% and 80%, respectively) patients. Mortality within 4 months of LT was twice as high in NASH as in non-NASH patients (8.5% vs. 4.2%; P = 0.04). Compared with non-NASH patients, post-LT mortality in NASH patients was more commonly caused by infectious (38% vs. 26%; P < 0.05) or cardiac (19% vs. 7%; P < 0.05) aetiologies. Five-year survival was lower in NASH patients with a high-risk phenotype (age >60 years, body mass index >30 kg/m(2), with hypertension and diabetes) than in NASH patients without these characteristics (72% vs. 87%; P = 0.02). Subgroup analyses revealed that 5-year overall survival in NASH was equivalent to that in Laennec's cirrhosis (85% vs. 80%; P 0.87), but lower than that in cirrhosis of cryptogenic aetiology (85% vs. 96%; P = 0.04).
CONCLUSIONS: Orthotopic LT in NASH was associated with increased early postoperative mortality, but 1-, 3- and 5-year overall survival rates were equivalent to those in non-NASH patients.
© 2012 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Year:  2012        PMID: 22882200      PMCID: PMC3461389          DOI: 10.1111/j.1477-2574.2012.00497.x

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  27 in total

Review 1.  Nonalcoholic fatty liver disease.

Authors:  Jeanne M Clark; Frederick L Brancati; Anna Mae Diehl
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

Review 2.  Nonalcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

3.  Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

Authors:  Elisabetta Bugianesi; Nicola Leone; Ester Vanni; Giulio Marchesini; Franco Brunello; Patrizia Carucci; Alessandro Musso; Paolo De Paolis; Lorenzo Capussotti; Mauro Salizzoni; Mario Rizzetto
Journal:  Gastroenterology       Date:  2002-07       Impact factor: 22.682

4.  Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States.

Authors:  Anita Afzali; Kristin Berry; George N Ioannou
Journal:  Liver Transpl       Date:  2012-01       Impact factor: 5.799

5.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.

Authors:  J B Dixon; P S Bhathal; P E O'Brien
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

6.  Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  P Angulo; J C Keach; K P Batts; K D Lindor
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

7.  Liver pathology in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery.

Authors:  Pierre M Gholam; Donald P Kotler; Louis J Flancbaum
Journal:  Obes Surg       Date:  2002-02       Impact factor: 4.129

8.  Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis.

Authors:  Vlad Ratziu; Luminita Bonyhay; Vincent Di Martino; Frederic Charlotte; Lucas Cavallaro; Marie-Hélène Sayegh-Tainturier; Philippe Giral; André Grimaldi; Pierre Opolon; Thierry Poynard
Journal:  Hepatology       Date:  2002-06       Impact factor: 17.425

9.  Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis.

Authors:  Jeanne M Clark; Anna Mae Diehl
Journal:  JAMA       Date:  2003-06-11       Impact factor: 56.272

10.  The prevalence and etiology of elevated aminotransferase levels in the United States.

Authors:  Jeanne M Clark; Frederick L Brancati; Anna Mae Diehl
Journal:  Am J Gastroenterol       Date:  2003-05       Impact factor: 10.864

View more
  15 in total

Review 1.  Non-alcoholic fatty liver disease and liver transplantation: outcomes and advances.

Authors:  Adnan Said
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

2.  Impact of renal impairment on cardiovascular disease mortality after liver transplantation for nonalcoholic steatohepatitis cirrhosis.

Authors:  Lisa B VanWagner; Brittany Lapin; Anton I Skaro; Donald M Lloyd-Jones; Mary E Rinella
Journal:  Liver Int       Date:  2015-06-03       Impact factor: 5.828

Review 3.  Metabolic syndrome and non-alcoholic fatty liver disease in liver surgery: The new scourges?

Authors:  François Cauchy; David Fuks; Alban Zarzavadjian Le Bian; Jacques Belghiti; Renato Costi
Journal:  World J Hepatol       Date:  2014-05-27

Review 4.  NAFLD and liver transplantation: Current burden and expected challenges.

Authors:  Raluca Pais; A Sidney Barritt; Yvon Calmus; Olivier Scatton; Thomas Runge; Pascal Lebray; Thierry Poynard; Vlad Ratziu; Filomena Conti
Journal:  J Hepatol       Date:  2016-07-30       Impact factor: 25.083

Review 5.  Implications of Nonalcoholic Steatohepatitis as the Cause of End-Stage Liver Disease Before and After Liver Transplant.

Authors:  Anchalia Chandrakumaran; Mohammad Shadab Siddiqui
Journal:  Gastroenterol Clin North Am       Date:  2020-03       Impact factor: 3.806

Review 6.  Peri-transplant management of nonalcoholic fatty liver disease in liver transplant candidates .

Authors:  Naga Swetha Samji; Rajiv Heda; Sanjaya K Satapathy
Journal:  Transl Gastroenterol Hepatol       Date:  2020-01-05

Review 7.  Nonalcoholic Fatty Liver Disease: Key Considerations Before and After Liver Transplantation.

Authors:  Yuval A Patel; Carl L Berg; Cynthia A Moylan
Journal:  Dig Dis Sci       Date:  2016-01-27       Impact factor: 3.199

Review 8.  Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians.

Authors:  Daniel Geh; Derek M Manas; Helen L Reeves
Journal:  Hepatobiliary Surg Nutr       Date:  2021-01       Impact factor: 8.265

9.  Early Intervention With Live Donor Liver Transplantation Reduces Resource Utilization in NASH: The Toronto Experience.

Authors:  Andrew S Barbas; Nicolas Goldaracena; Martin J Dib; David P Al-Adra; Aloysious D Aravinthan; Leslie B Lilly; Eberhard L Renner; Nazia Selzner; Mamatha Bhat; Mark S Cattral; Anand Ghanekar; Ian D McGilvray; Gonzalo Sapisochin; Markus Selzner; Paul D Greig; David R Grant
Journal:  Transplant Direct       Date:  2017-05-10

Review 10.  A clinical perspective of the link between metabolic syndrome and hepatocellular carcinoma.

Authors:  François Cauchy; Jacques Belghiti
Journal:  J Hepatocell Carcinoma       Date:  2015-02-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.